Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation

Cancer Science

Volumn 104, Issue 10, 2013, Pages 1315-1322

  Sato, Kanae ^a   Shin, Myoung Sook ^a   Sakimura, Ayaka ^a   Zhou, Yue ^a   Tanaka, Tomohiro ^a   Kawanishi, Miho ^a   Kawasaki, Yuki ^a   Yokoyama, Satoru ^a   Koizumi, Keiichi ^a   Saiki, Ikuo ^a   Sakurai, Hiroaki ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HOMODIMER; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN; SYNAPTOPHYSIN; THR 669 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; LUNG ADENOCARCINOMA; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; WILD TYPE;

ADENOCARCINOMA; BREAST NEOPLASMS; BUTADIENES; CELL LINE, TUMOR; DIMERIZATION; EPIDERMAL GROWTH FACTOR; FEEDBACK, PHYSIOLOGICAL; FEMALE; HUMANS; LIGANDS; MAP KINASE SIGNALING SYSTEM; NEOPLASM PROTEINS; NEUREGULIN-1; NITRILES; PHOSPHORYLATION; PHOSPHOTHREONINE; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884989551     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12225     Document Type: Article

References (33)

1. Sebastian S, Settleman J, Reshki SJ et al. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 2006; 1766: 120-39.
2. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol 2009; 218: 460-6.
3. Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 2005; 17: 1183-93.
4. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2008; 314: 3093-106.
5. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 2011; 12: 104-17.
6. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
7. Paez J, Jänne P, Lee J et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
8. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-81.
9. Zhang H, Berezov A, Wang Q et al. ErbB receptors: From oncogenes to targeted cancer therapies. J Clin Invest 2007; 117: 2051-8.
10. Morandell S, Stasyk T, Skvortsov S, Ascher S, Huber LA. Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. Proteomics 2008; 8: 4383-401.
11. Nakakuki T, Yumoto N, Naka T et al. Topological analysis of MAPK cascade for kinetic ErbB signaling. PLoS ONE 2008; 3: e1782.
12. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006; 125: 1137-49.
13. Hubbard SR. EGF receptor activation: push comes to shove. Cell 2006; 125: 1029-31.
14. Thiel KW, Carpenter G. Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation. Proc Natl Acad Sci USA 2007; 104: 19238-43.
15. Jura N, Endres NF, Engel K et al. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009; 137: 1293-307.
16. Red Brewer M, Choi SH, Alvarado D et al. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 2009; 34: 641-51.
17. Zwang Y, Yarden Y. p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J 2006; 25: 4195-206.
18. Singhirunnusorn P, Ueno Y, Matsuo M et al. Transient suppression of ligand-mediated activation of epidermal growth factor receptor by tumor necrosis factor-alpha through the TAK1-p38 signaling pathway. J Biol Chem 2007; 282: 12698-706.
19. Nishimura M, Shin MS, Singhirunnusorn P et al. TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-{kappa}B-independent survival pathways in tumor necrosis factor alpha signaling. Mol Cell Biol 2009; 29: 5529-39.
20. Vergarajauregui S, San Miguel A, Puertollano R. Activation of p38 mitogen-activated protein kinase promotes epidermal growth factor receptor internalization. Traffic 2006; 7: 686-98.
21. Winograd-Katz SE, Levitzki A. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene 2006; 25: 7381-90.
22. Adachi S, Natsume H, Yamauchi J et al. p38 MAP kinase controls EGF receptor downregulation via phosphorylation at Ser 1046/1047. Cancer Lett 2009; 277: 108-13.
23. Li X, Huang Y, Jiang J, Frank SJ. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell Signal 2008; 20: 2145-55.
24. Sakurai H, Miyoshi H, Toriumi W, Sugita T. Functional interactions of transforming growth factor beta-activated kinase 1 with IkappaB kinases to stimulate NF-kappaB activation. J Biol Chem 1999; 274: 10641-8.
25. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010; 7: 683-92.
26. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
27. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-8.
28. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-64.
29. Gill S, Goldberg RM. Cetuximab, chemotherapy and KRAS status in mCRC. Nat Rev Clin Oncol 2009; 6: 379-80.
30. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
31. Kubota Y, O'Grady P, Saito H, Takekawa M. Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation. Nat Cell Biol 2011; 13: 282-91.
32. Maraver A, Fernandez-Marcos PJ, Herranz D et al. Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 2012; 22: 222-34.
33. Prahallad A, Sun C, Huang S et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-3.